Researchers at the Medical University of South Carolina are testing a possible treatment for multisystem inflammatory syndrome, MIS-C, a rare but serious complication of COVID-19 in children. The syndrome can cause inflammation in the heart, lungs, kidneys, brain, skin, eyes, and gastrointestinal organs. One MUSC Health pediatrician described MIS-C as an immune response to the virus “gone haywire.”
The syndrome has only affected seven children in South Carolina since the start of the pandemic. All have recovered. But MIS-C is blamed for killing children in other states, including Louisiana and Colorado.
The Regenerative Therapy
The treatment was developed by the company Mesoblast for another purpose: to try to help people who have had bone marrow transplants by keeping their bodies from rejecting the transplanted tissue. This regenerative therapy could be an MIS-C fighter because, like the body’s reaction to a bone marrow transplant, MIS-C is a harmful immune system reaction to a perceived enemy. Research suggests remestemcel-L is safe for children, one of the important thresholds in clinical research. A very small study indicates it may...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).